Lange R, Ingwall J, Hale S L, Alker K J, Braunwald E, Kloner R A
Circulation. 1984 Oct;70(4):734-41. doi: 10.1161/01.cir.70.4.734.
To determine whether verapamil prevents depletion of adenine nucleotides during and after severe myocardial ischemia, dogs were subjected to 15 min occlusions of the left anterior descending coronary artery followed by 240 min of reperfusion. One hour before occlusion, dogs were randomly assigned to a treatment group (n = 10) to which an infusion of intravenous verapamil was given until the onset of reperfusion or to an untreated saline group (n = 9). Verapamil reduced mean aortic pressure and heart rate. After 15 min of ischemia, endocardial adenosine triphosphate (ATP) level, determined by needle biopsy, decreased in the untreated group from 34.7 +/- 2.0 to 24.4 +/- 2.7 nmol X mg protein-1 (p less than .005 vs preocclusion) and in the verapamil group from 32.8 +/- 1.5 to 30.3 +/- 1.5 nmol X mg protein-1 (NS vs preocclusion). Dogs receiving verapamil had significantly higher ATP levels than untreated animals after 90 and 240 min of reperfusion. In untreated animals the sum of inosine and hypoxanthine levels increased during occlusion from very low levels to 4.6 +/- 1.1 nmol X mg protein-1 in the epicardium and to 6.8 +/- 1.5 nmol X mg protein-1 in the endocardium (p less than .05 compared with preocclusion values). In verapamil-treated dogs inosine and hypoxanthine levels increased to only 1.2 +/- 0.3 (epicardium) and 1.9 +/- 0.6 nmol X mg protein-1 (endocardium) (both NS compared with preocclusion values). After 90 min of reperfusion the sum of ATP, adenosine diphosphate, adenosine monophosphate, inosine, and hypoxanthine levels was decreased in the endocardium by 10.2 nmol X mg protein-1 in the untreated group, but no change was observed in verapamil-treated animals. We conclude that breakdown of ATP to inosine and hypoxanthine during severe ischemia is reduced by verapamil, resulting in higher ATP concentrations during occlusion and reperfusion and decreased washout of the diffusible purines inosine and hypoxanthine during reperfusion.
为了确定维拉帕米是否能预防严重心肌缺血期间及之后腺嘌呤核苷酸的耗竭,对犬进行左前降支冠状动脉15分钟闭塞,随后再灌注240分钟。在闭塞前1小时,将犬随机分为治疗组(n = 10),给予静脉输注维拉帕米直至再灌注开始,或分为未治疗的生理盐水组(n = 9)。维拉帕米降低了平均主动脉压和心率。缺血15分钟后,通过针吸活检测定的心内膜三磷酸腺苷(ATP)水平,未治疗组从34.7±2.0降至24.4±2.7 nmol·mg蛋白⁻¹(与闭塞前相比,p<0.005),维拉帕米组从32.8±1.5降至30.3±1.5 nmol·mg蛋白⁻¹(与闭塞前相比,无显著性差异)。再灌注90分钟和240分钟后,接受维拉帕米治疗的犬的ATP水平显著高于未治疗的动物。在未治疗的动物中,闭塞期间肌苷和次黄嘌呤水平之和从极低水平增加到心外膜的4.6±1.1 nmol·mg蛋白⁻¹和心内膜的6.8±1.5 nmol·mg蛋白⁻¹(与闭塞前值相比,p<0.05)。在维拉帕米治疗组的犬中,肌苷和次黄嘌呤水平仅增加到1.2±0.3(心外膜)和1.9±0.6 nmol·mg蛋白⁻¹(心内膜)(与闭塞前值相比,均无显著性差异)。再灌注90分钟后,未治疗组心内膜中ATP、二磷酸腺苷、一磷酸腺苷、肌苷和次黄嘌呤水平之和降低了10.2 nmol·mg蛋白⁻¹,但维拉帕米治疗的动物未观察到变化。我们得出结论,维拉帕米可减少严重缺血期间ATP分解为肌苷和次黄嘌呤,导致闭塞和再灌注期间ATP浓度升高,并减少再灌注期间可扩散嘌呤肌苷和次黄嘌呤的洗脱。